References 563 & 102. Liu S, Gao A, Zhang B, Zhang Z, Zhao Y, Chen P, et al. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population. Experimental and molecular pathology. 2014;97:292-297. https://doi.org/10.1016/j.yexmp.2014.08.005. 103. Poller DN, Glaysher S, Agrawal A, Caldera S, Kim D, Yiangou C. BRAF V600 co-testing in thyroid FNA cytology: shortterm experience in a large cancer centre in the UK. Journal of clinical pathology. 2014;67:684-689. https://doi. org/10.1136/jclinpath-2014-202348. 104. Seo JY, Kim EK, Kwak JY. Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with “suspicious for malignant” cytology alone even when the nodules do not show suspicious US features. Endocrine. 2014;47:283-289. https://doi.org/10.1007/s12020-013-0150-5. 105. Borrelli N, Ugolini C, Giannini R, Antonelli A, Giordano M, Sensi E, et al. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis. Cancer cytopathology. 2015. https://doi.org/10.1002/ cncy.21681. 106. Capelli L, Marfisi C, Puccetti M, Saragoni L, De Paola F, Zaccaroni A, et al. Role of BRAF molecular analysis in the management of papillary thyroid carcinoma: analysis of cytological and histological samples. Cytopathology. 2015;26:297-302. https://doi.org/10.1111/cyt.12199. 107. Gill MS, Nayan S, Kocovski L, Cutz JC, Archibald SD, Jackson BS, et al. Local molecular analysis of indeterminate thyroid nodules. Journal of otolaryngology - head & neck surgery. 2015;44:52. https://doi.org/10.1186/s40463-0150106-2. 108. Giovanella L, Campenni A, Treglia G, Verburg FA, Trimboli P, Ceriani L, et al. Molecular imaging with Tc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison. European journal of nuclear medicine and molecular imaging. 2015. https://doi.org/10.1007/s00259015-3285-1. 109. Le Mercier M, D’Haene N, De Neve N, Blanchard O, Degand C, Rorive S, et al. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology. 2015;66:215-224. https://doi. org/10.1111/his.12461. 110. Marino M, Monzani ML, Brigante G, Cioni K, Madeo B, Santi D, et al. High-Resolution Melting Is a Sensitive, CostEffective, Time-Saving Technique for BRAF V600E Detection in Thyroid FNAB Washing Liquid: A Prospective Cohort Study. European Thyroid Journal. 2015;4:73-81. 111. Park KS, Oh YL, Ki CS, Kim JW. Evaluation of the Real-Q BRAF V600E Detection Assay in Fine-Needle Aspiration Samples of Thyroid Nodules. The Journal of molecular diagnostics. 2015;17:431-437. https://doi.org/10.1016/j. jmoldx.2015.03.006. 112. Beisa A, Beisa V, Stoskus M, Ostaneviciute E, Griskevicius L, Strupas K. The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer. Endokrynologia Polska. 2016;67:35-40. https://doi.org/10.5603/ep.2016.0005. 113. Kowalska A, Kowalik A, Palyga I, Walczyk A, Gasior-Perczak D, Kopczynski J, et al. The usefulness of determining the presence of BRAF V600E mutation in fine-needle aspiration cytology in indeterminate cytological results. Endokrynologia Polska. 2016;67:41-47. https://doi.org/10.5603/ep.2016.0006. 114. Valderrabano P, Leon ME, Centeno BA, Otto KJ, Khazai L, McCaffrey JC, et al. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. European journal of endocrinology / European Federation of Endocrine Societies. 2016. https://doi.org/10.1530/eje-15-1163. 115. Kim SW, Lee JI, Kim JW, Ki CS, Oh YL, Choi YL, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. The Journal of clinical endocrinology and metabolism. 2010;95:3693-3700. https://doi.org/10.1210/jc.2009-2795. 116. Koh J, Choi JR, Han KH, Kim EK, Yoon JH, Moon HJ, et al. Proper indication of BRAF(V600E) mutation testing in fineneedle aspirates of thyroid nodules. PloS one. 2013;8:e64505. https://doi.org/10.1371/journal.pone.0064505. 117. Leslie C, Grieu-Iacopetta F, Richter A, Platten M, Murray J, Frost FA, et al. BRAF p.Val600Glu (V600E) mutation detection in thyroid fine needle aspiration cell block samples: a feasibility study. Pathology. 2015;47:432-438. https://doi.org/10.1097/pat.0000000000000273. 118. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120:3627-3634. https://doi.org/10.1002/cncr.29038. 119. Jeong SH, Hong HS, Lee EH, Cha JG, Park JS, Kwak JJ. Outcome of thyroid nodules characterized as atypia of undetermined significance or follicular lesion of undetermined significance and correlation with Ultrasound features and BRAF(V600E) mutation analysis. AJR American journal of roentgenology. 2013;201:W854-860. https://doi. org/10.2214/ajr.12.9901. 120. Hyeon J, Ahn S, Shin JH, Oh YL. The prediction of malignant risk in the category “atypia of undetermined significance/follicular lesion of undetermined significance” of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results. Cancer cytopathology. 2014;122:368-376. https://doi.org/10.1002/cncy.21396.
RkJQdWJsaXNoZXIy MTk4NDMw